Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2017
Pharmacy Choice - News - Generic Drugs - May 30, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 47     Next >>     Go To Page:

5/29/17 - Former Pharma Executives Settle With States
Two former executives of a New Jersey- based drugmaker have entered into agreements with Connecticut and 40 other states to cooperate in an ongoing antitrust investigation. Jason Malek, former president of Heritage Pharmaceuticals Inc., and Jeffrey Glazer, former chairman and CEO of the company, have reached settlement agreements in which they will
5/29/17 - Glenmark Pharmaceuticals receives ANDA approval for Nebivolol Tablets [India Infoline News Service]
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, the generic version of Bystolic Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, of Forest Laboratories, LLC. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United
5/29/17 - Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
Release date- 26052017- TORONTO- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled release and targeted release oral solid dosage drugs, today announced that, in order to replace its existing expiring shelf registration statement, it has filed
5/29/17 - Lannett Announces Approval For Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL 0.5 mg/mL
By a News Reporter-Staff News Editor at Pharma Business Week Lannett Company, Inc. announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL, the therapeutic equivalent to the reference listed drug, Xyzal Oral Solution, 2.
5/29/17 - Pharmadax Receives FDA Approval for a Generic Version of Seroquel XR
By a News Reporter-Staff News Editor at Pharma Business Week Pharmadax Inc., a pharmaceutical company based in New Taipei City, Taiwan, and its subsidiary Pharmadax USA, Inc., based in Irvine, California, announced that U.S. Food and Drug Administration has approved a generic equivalent to Seroquel XR ER tablets, 50 mg, 150 mg, 200 mg, 300 mg
5/29/17 - Statement Regarding Xifaxan Intellectual Property Litigation
By a News Reporter-Staff News Editor at Pharma Business Week Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. and Actavis Laboratories, Inc., at Actavis' request, have agreed to stay outstanding litigation and extend the 30- month stay regarding Actavis' Abbreviated New Drug application for a generic version of X
5/29/17 - Successful US patent strategy - Oncology Ventures Irofulven Claims Accepted
Hoersholm; May 29, 2017- Medical Prognosis Institute today announced that Oncology Venture a spinout from MPI using MPI's DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor for Oncology Ventures anticancer drug Irofulven. "The granting of the paten
5/29/17 - Teva Announces Launch of Generic Glumetza in the United States
By a News Reporter-Staff News Editor at Diabetes Week Teva Pharmaceutical Industries Ltd., announced the launch of generic Glumetza 1, 500 mg and 1000 mg, in the U.S. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opport
5/29/17 - Two Day Biosimilar from Development to Registration Course (Morrisville, United States - August 3-4, 2017)
Dublin- Research and Markets has announced the addition of the "Biosimilar from Development to Registration" conference to their offering. This course will provide attendees with a concise but comprehensive overview of all relevant regulatory, technical and quality elements necessary to assure successful market access. The regulation of Biosimilars
5/29/17 - Two Day Biosimilar from Development to Registration Course (Morrisville, United States - August 3-4, 2017) - Research and Markets
Research and Markets has announced the addition of the "Biosimilar from Development to Registration" conference to their offering. This course will provide attendees with a concise but comprehensive overview of all relevant regulatory, technical and quality elements necessary to assure successful market access. Research and Markets Laura Wood, Seni
5/28/17 - 5 Top NASDAQ Biotech Stocks: Nutraceutical Gained 48.93 Percent
Last week the Congressional Budget Office revealed the GOP replacement to Obamacare would end up nixing insurance coverage to 26 million american citizens by 2026 in an attempt to reduce $119 billion over the next decade. FDA head Scott Gottlieb announced it would remove the federal hiring freeze to his agency. Nutraceutical CytRx MannKind MEI Phar
5/28/17 - Purchase Along With The Delivery Of Oncological Drugs, Generic Drugs And Nutrition For The Hospital Pharmacy Of The Swietokrzyskie Center Of Oncology In Kielce. [TendersInfo (India)]
Contract notice: Purchase along with the delivery of oncological drugs, generic drugs and nutrition for the hospital pharmacy of the Swietokrzyskie center of oncology in kielce. Detailed description of the object of the order together with specification of assortment, quantity and quality requirements falling within the scope of the subject of...
5/27/17 - Attorney General Becerra Announces $33M Nationwide Settlement After Maker of Tylenol, Motrin, Benadryl Produced Adulterated Medicine
California Attorney General Xavier Becerra issued the following news release:. California Attorney General Xavier Becerra announced a $33 million settlement with drug manufacturer Johnson& Johnson after it violated federal regulations between 2009 and 2011 that ensure the quality of certain medicines, including many consumed by children.
5/27/17 - FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson [T-break Tech (Middle East)]
Pfizers biosimilar to blockbuster anemia meds Epogen and Procrit won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval. Indeed, ahead of the panels meeting, FDA reviewers called the Pfizer med highly similar to the reference product, epoetin alfa, sold by Amgen as Epogen and Johnson& Johnson under th
5/27/17 - Glenmark gets USFDA`s approval to sell generic blood pressure medicine [Sudan Tribune]
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure. The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company sa
5/27/17 - Hogan lets drug price-gouging bill, dozens of others become law without signature [The Baltimore Sun]
Larry Hogan said Friday he will not block a new law giving the Maryland attorney general's office authority to take generic drug makers to court to challenge allegedly excessive price increases. The Republican governor's actions resolve the final questions surrounding the disposition of bills considered by the General Assembly in the 90- day sessio
5/27/17 - Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement [Sport360]
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, in order to replace its existing expiring shelf registration statement, it has filed a new shelf registration...
5/27/17 - McCaskill, Collins Effort to Tackle Cost of Rx Drugs Clears Key Committee Hurdle
Claire McCaskill, D- Mo., issued the following news release:. A bipartisan plan from U.S. Senator Claire McCaskill and Republican Senator Susan Collins of Maine to combat the sudden, aggressive price hikes of generic drugs by promoting competition to help lower costs and improve accessibility cleared a key committee hurdle today and now advances to
5/27/17 - New FDA Commissioner reveals strategy to drive down drug prices [Tehran Times (Iran)]
According to Gottlieb, the FDA is currently working on a drug competition action plan which is designed particularly to accelerate the approval of generic drugs which face no competition. Gottlieb told a congressional panel that he aims for the FDA to take a more active role in the pricing of drugs, noting: While FDA does not play a direct role in
5/26/17 - Cosunter Pharmaceutical Viread Generic Drug Nodded
FUJIAN, May 26, SinoCast Reporters noticed that Fujian Cosunter Pharmaceutical Co., Ltd. has gotten registration approval for making generic drug of Viread curing HBV, since existing HBV drugs are facing risk for declining sales volume, dragging down net profit. In 2016, Cosunter Pharmaceutical harvested operating revenue climbing 1.28% from a ye
5/26/17 - FDA Panel Recommends Approval Of Epoetin Alfa Biosimilar Across All Indications
NEW YORK CITY- Pfizer Inc. said that the United States Food and Drug Administration Oncologic Drugs Advisory Committee recommended to approve Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent has been recommended for approval by a U.S. FDA Advisory Committee.
5/26/17 - Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, in order to replace its existing expiring shelf registration statement, it has filed a new shelf registration...
5/26/17 - NINLARO Capsules Now Available for the Treatment of Multiple Myeloma in Japan
Release date- 24052017- Osaka, Japan- Takeda Pharmaceutical Company Limited today announced that NINLARO capsules are now available in Japan. NINLARO is the first oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone, for which Takeda has obtained the New Drug Application Approval for the treatment of patients with
5/26/17 - Pharmaceutical Packaging Equipment Market to Reach $8.24 Billion by 2022 - Driven by Growth in Funding For Generics & Biopharmaceutical Research - Research and Markets
Research and Markets has announced the addition of the "Pharmaceutical Packaging Equipment Market- Global Forecast to 2022" report to their offering. The global pharmaceutical packaging equipment market is projected to reach approximately USD 8.24 Billion by 2022 at an approximate CAGR of 6.8% during the forecast period. The growth of the pharmaceu
5/26/17 - Studies in the Area of Social and Administrative Pharmacy Reported from Faculty of Pharmacy (Translation and validation of the Arabic version of...
Studies in the Area of Social and Administrative Pharmacy Reported from Faculty of Pharmacy. By a News Reporter-Staff News Editor at Drug Week Data detailed on Drugs and Therapies- Social and Administrative Pharmacy have been presented. According to news reporting from Irbid, Jordan, by NewsRx journalists, research stated, "Generic drugs are cons
Articles(s): 1 - 25 of 47     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415